Literature DB >> 20848638

Clinicopathologic comparison of familial versus sporadic atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system.

Carol S Bruggers1, Steven B Bleyl, Theodore Pysher, Philip Barnette, Zeinab Afify, Marion Walker, Jaclyn A Biegel.   

Abstract

BACKGROUND: Central nervous system (CNS) atypical teratoid/rhabdoid tumors (AT/RT) are aggressive tumors usually diagnosed in young children and characterized by SMARCB1 (INI1, hSNF5) gene abnormalities. Despite initial chemo-radiation responsiveness, most children die of progressive disease (PD). Little data regarding familial AT/RT clinical course exist. This study described and compared familial (F) versus sporadic (S) AT/RT and elucidated SMARCB1 mutations and inheritance patterns.
METHODS: A retrospective chart review, pedigree, and SMARCB1 analysis were done.
RESULTS: Between January 1989 and June 2009, 20 children with CNS AT/RT were diagnosed, 8-S and 12-F. Median age at diagnosis (months) of S and F patient were: 13 and 4.8, respectively. Median survival (months) was S-21, F4.5, and 8-all. Pedigree analyses showed unaffected parent carriers with multiple affected offspring.
CONCLUSIONS: Children with F-AT/RT are younger, have more extensive disease, and are more likely to die from PD than children with S-AT/RT. Surgery, radiation, and chemotherapy were important in achieving long-term survival. Pedigree analysis supports autosomal dominant inheritance pattern with incomplete penetrance. Germline SMARCB1 mutation analysis is important in all patients diagnosed with AT/RT to (1) determine actual incidence of F-AT/RT, (2) determine penetrance of predisposing mutations, (3) provide appropriate genetic counseling, and (4) establish surveillance screening guidelines.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848638      PMCID: PMC3210729          DOI: 10.1002/pbc.22757

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  33 in total

1.  Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations.

Authors:  N Sévenet; A Lellouch-Tubiana; D Schofield; K Hoang-Xuan; M Gessler; D Birnbaum; C Jeanpierre; A Jouvet; O Delattre
Journal:  Hum Mol Genet       Date:  1999-12       Impact factor: 6.150

2.  Chromosome 22q deletions in atypical teratoid/rhabdoid tumors in adults.

Authors:  Jack Raisanen; Jaclyn A Biegel; Kimmo J Hatanpaa; Alexander Judkins; Charles L White; Arie Perry
Journal:  Brain Pathol       Date:  2005-01       Impact factor: 6.508

3.  Simultaneous presentation of atypical teratoid/rhabdoid tumor in siblings.

Authors:  F Proust; A Laquerriere; B Constantin; M M Ruchoux; J P Vannier; P Fréger
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

Review 4.  Treatment of primary malignant rhabdoid tumor of the brain: report of three cases and review of the literature.

Authors:  E Weiss; B Behring; J Behnke; H J Christen; A Pekrun; C F Hess
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-07-15       Impact factor: 7.038

5.  Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry.

Authors:  Joanne M Hilden; Sharon Meerbaum; Peter Burger; Jonathan Finlay; Anna Janss; Bernd W Scheithauer; Andrew W Walter; Lucy B Rorke; Jaclyn A Biegel
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

6.  Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors.

Authors:  Sharon L Gardner; Shahab Asgharzadeh; Adam Green; Biljana Horn; Geoffrey McCowage; Jonathan Finlay
Journal:  Pediatr Blood Cancer       Date:  2008-08       Impact factor: 3.167

7.  Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop.

Authors:  Roger J Packer; Jaclyn A Biegel; Susan Blaney; Jonathan Finlay; J Russell Geyer; Richard Heideman; Joanne Hilden; Anna J Janss; Larry Kun; Gilbert Vezina; Lucy B Rorke; Malcolm Smith
Journal:  J Pediatr Hematol Oncol       Date:  2002 Jun-Jul       Impact factor: 1.289

8.  Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood.

Authors:  L B Rorke; R Packer; J Biegel
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  Atypical teratoid rhabdoid tumor (AT/RT) in adults: review of four cases.

Authors:  Addisalem T Makuria; Elisabeth J Rushing; Kevin M McGrail; Dan-Paul Hartmann; Norio Azumi; Metin Ozdemirli
Journal:  J Neurooncol       Date:  2008-03-28       Impact factor: 4.130

10.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.

Authors:  I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre
Journal:  Nature       Date:  1998-07-09       Impact factor: 49.962

View more
  24 in total

1.  Epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with "neuroblastoma-like" schwannomatosis and a novel germline SMARCB1 mutation.

Authors:  Jodi M Carter; Carolyn O'Hara; George Dundas; Dawna Gilchrist; Mark S Collins; Katherine Eaton; Alexander R Judkins; Jaclyn A Biegel; Andrew L Folpe
Journal:  Am J Surg Pathol       Date:  2012-01       Impact factor: 6.394

Review 2.  Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis.

Authors:  Till Holsten; Susanne Bens; Florian Oyen; Karolina Nemes; Martin Hasselblatt; Uwe Kordes; Reiner Siebert; Michael C Frühwald; Reinhard Schneppenheim; Ulrich Schüller
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

3.  High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival.

Authors:  Diane K Birks; Andrew M Donson; Purvi R Patel; Christopher Dunham; Andrea Muscat; Elizabeth M Algar; David M Ashley; B K Kleinschmidt-Demasters; Rajeev Vibhakar; Michael H Handler; Nicholas K Foreman
Journal:  Neuro Oncol       Date:  2011-09-23       Impact factor: 12.300

4.  Atypical teratoid/rhabdoid tumor in the sella turcica of an elderly female with a distinct vascular pattern and genetic alterations.

Authors:  Sumihito Nobusawa; Satoshi Nakata; Junko Hirato; Takahiro Kawashima; Koji Sato; Hiroya Fujimaki; Naoki Okura; Hayato Ikota; Hideaki Yokoo
Journal:  Virchows Arch       Date:  2016-09-05       Impact factor: 4.064

5.  Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.

Authors:  Cynthia Wetmore; James Boyett; Shaoyu Li; Tong Lin; Anne Bendel; Amar Gajjar; Brent A Orr
Journal:  Neuro Oncol       Date:  2015-02-16       Impact factor: 12.300

6.  Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome.

Authors:  Santhosh A Upadhyaya; Rose B McGee; Breelyn A Wilky; Alberto Broniscer
Journal:  Pediatr Blood Cancer       Date:  2018-03-07       Impact factor: 3.167

7.  p16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors.

Authors:  Sriram Venneti; Paul Le; Daniel Martinez; Katherine W Eaton; Nikhil Shyam; Kelly L Jordan-Sciutto; Bruce Pawel; Jaclyn A Biegel; Alexander R Judkins
Journal:  J Neuropathol Exp Neurol       Date:  2011-07       Impact factor: 3.685

8.  Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors.

Authors:  Mark W Kieran; Charles W M Roberts; Susan N Chi; Keith L Ligon; Benjamin E Rich; Laura E Macconaill; Levi A Garraway; Jaclyn A Biegel
Journal:  Pediatr Blood Cancer       Date:  2012-09-19       Impact factor: 3.167

9.  Evaluation of osteopontin as a potential biomarker for central nervous system embryonal tumors.

Authors:  Yi-Peng Han; Chen-Kai Ma; Shen-Qi Wang; Atsushi Enomoto; Yang Zhao; Masahide Takahashi; Jie Ma
Journal:  J Neurooncol       Date:  2014-05-31       Impact factor: 4.130

Review 10.  Intracranial cystic lesions: a review.

Authors:  Sophie Taillibert; Emilie Le Rhun; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.